S-1/A: IMAC Holdings Eyes $60 Million Capital Injection via Equity Line with Keystone Capital Partners

IMAC Holdings plans to potentially raise up to $60 million through an equity line of credit with Keystone Capital Partners, while navigating Nasdaq compliance challenges.

Summary

• IMAC Holdings, Inc. has filed an amendment to its Form S-1 registration statement for a potential offering involving the resale of up to 35,007,025 shares of common stock by Keystone Capital Partners, LLC.
• The shares may be issued to Keystone under a Common Stock Purchase Agreement establishing an equity line of credit, potentially providing IMAC with up to $60 million in gross proceeds.
• The actual number of shares issued will depend on the market price of IMAC's common stock and other conditions.
• IMAC intends to use 25% of the net proceeds to redeem outstanding preferred stock and the remainder for working capital and general corporate purposes.
• The company is currently facing challenges with Nasdaq listing requirements, including maintaining minimum stockholders' equity and bid price, and has requested an appeal of a delisting determination.
• IMAC's strategy involves increasing revenue through higher volume sample analysis of its proteomic products, aiming to establish its technology as a standard of care.
• The company's product portfolio includes the Ignite RPPA Assay for Breast Cancer, with plans to expand to other cancer types.
• Recent developments include the termination of a merger agreement with Theralink Technologies, Inc., and the acquisition of certain assets and rights from Theralink.
• Leadership changes have occurred, with Faith Zaslavsky appointed as the new Chief Executive Officer.
• The company is a smaller reporting company and may take advantage of certain scaled disclosures.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. The potential capital injection is positive, but the Nasdaq compliance issues and potential dilution are concerning. The company's strategic focus on proteomic assays is promising, but the risks associated with the equity financing and regulatory landscape temper the overall outlook.

Positives

• The committed equity financing with Keystone Capital Partners could provide IMAC with up to $60 million in gross proceeds.
• The company intends to use a portion of the proceeds to redeem outstanding preferred stock.
• IMAC is focused on expanding the utilization of its proteomic assay and achieving formal guideline inclusion.
• The company has compelling clinical data showing that its reverse phase protein array (RPPA) analysis can predict which patients will respond or fail to respond to targeted therapies and immunotherapies.
• The Ignite RPPA Assay for Breast Cancer is currently being utilized, with plans to launch assays for other cancer types.

Negatives

• IMAC is facing potential delisting from Nasdaq due to non-compliance with minimum equity rules.
• The company has received notices from Nasdaq regarding non-compliance with listing rules.
• The actual proceeds from the sale of shares to Keystone may be less than the potential $60 million.
• The company may not have access to the full amount available under the Purchase Agreement.
• The purchase price of common stock to be sold to Keystone under the Purchase Agreement is derived from the market price of our common stock on Nasdaq and will be purchased at a discounted price.

Risks

• The actual number of shares issued to Keystone and the resulting dilution to existing shareholders is uncertain.
• IMAC may not have access to the full amount available under the Purchase Agreement.
• Sales of common stock to Keystone could cause the price of IMAC's common stock to decline.
• The company's inability to access a portion or the full amount available under the Purchase Agreement, in the absence of any other financing sources, could have a material adverse effect on our business or results of operation.
• The company is not in compliance with the NASDAQ Capital Market $1.00 minimum bid price requirement and the $2,500,000 stockholders equity minimum requirement which could result in delisting and adversely affect the market price and liquidity of our common stock.
• The FDA's newly issued rule for LDTs, effective July 5, 2024, which will be phased in over a period of four years, will significantly change the regulatory landscape for LDTs.

Future Outlook

IMAC expects to increase revenue by increasing volume sample analysis and aims to establish its technology as a standard of care by achieving formal guideline inclusion.

Industry Context

The announcement reflects a company in the healthcare sector seeking capital to expand its proteomic services, a field gaining prominence in personalized medicine and drug development. The company's focus on oncology and partnerships with universities aligns with industry trends towards targeted therapies and biomarker-driven treatment decisions.

Comparison to Industry Standards

• The Reverse Phase Protein Array (RPPA) technology is used by companies like Thermo Fisher Scientific and Cell Signaling Technology, but IMAC's application is focused on oncology clinical treatment decisions and biopharmaceutical drug development.
• The equity financing strategy is similar to that used by other small-cap biotech companies to fund research and development, such as those used by companies like Sorrento Therapeutics and Cassava Sciences.
• The challenges with Nasdaq compliance are common among smaller companies in the biotech sector, as seen with companies like Diffusion Pharmaceuticals and Evofem Biosciences.

Management Changes

Stakeholder Impact

• Shareholders may experience dilution due to the potential issuance of a large number of shares to Keystone.
• Employees may be affected by the company's financial performance and ability to maintain Nasdaq listing.
• Customers (oncologists and biopharmaceutical companies) may benefit from the expansion of IMAC's proteomic services.
• Suppliers and creditors may be impacted by the company's financial stability and ability to meet its obligations.

Next Steps

• IMAC will seek stockholder approval for the issuance of shares to Keystone.
• The company will continue to pursue its appeal of Nasdaq's delisting determination.
• IMAC plans to launch assays for other cancer types beyond breast cancer.
• The company will monitor and comply with the FDA's new rules concerning LDT regulation.

Key Dates

Keywords

equity financing, Keystone Capital Partners, common stock, Nasdaq, proteomics, RPPA, delisting, Ignite Proteomics, Theralink, preferred stock